Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis

Le résumé fourni par la source

To investigate outcomes in adults with type 2 diabetes who switched to once-weekly (OW) semaglutide from another glucagon-like peptide-1 receptor agonist (GLP-1RA) in clinical practice. This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice. Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA1c), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA1c value within the 12 weeks before switching to OW semaglutide. In addition, descriptive statistics were used for HbA1c, body weight target achievement, and safety data. Of the 3,505 patients included in the nine SURE studies, 651 switched to OW semaglutide from another GLP-1RA. GLP-1RA-experienced patients who switched to OW semaglutide demonstrated a 0.67%-point [95% confidence interval (CI) − 0.74; − 0.60, p < 0.0001] reduction in HbA1c, and a 3.69-kg [95% CI − 3.98; − 3.41, p < 0.0001] reduction in body weight over 30 weeks. A body weight reduction of ≥ 5% was achieved by 27.6% of patients, and 33.3% of patients with baseline HbA1c ≥ 7% achieved HbA1c < 7% at end of study. No new safety concerns were identified. Data from this post hoc analysis suggest that, for those not adequately responding to treatment with other GLP-1RAs, switching to OW semaglutide could provide additional glycemic and weight benefits with the convenience of an OW dosing regimen. A graphical abstract is available with this article.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.